Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2010 1
2011 1
2012 3
2013 1
2017 1
2018 2
2020 1
2021 3
2022 3
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Results by year

Filters applied: . Clear all
Page 1
Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders.
Ringelstein M, Ayzenberg I, Lindenblatt G, Fischer K, Gahlen A, Novi G, Hayward-Könnecke H, Schippling S, Rommer PS, Kornek B, Zrzavy T, Biotti D, Ciron J, Audoin B, Berthele A, Giglhuber K, Zephir H, Kümpfel T, Berger R, Röther J, Häußler V, Stellmann JP, Whittam D, Jacob A, Kraemer M, Gueguen A, Deschamps R, Bayas A, Hümmert MW, Trebst C, Haarmann A, Jarius S, Wildemann B, Grothe M, Siebert N, Ruprecht K, Paul F, Collongues N, Marignier R, Levy M, Karenfort M, Deppe M, Albrecht P, Hellwig K, Gold R, Hartung HP, Meuth SG, Kleiter I, Aktas O; Neuromyelitis Optica Study Group (NEMOS). Ringelstein M, et al. Among authors: zephir h. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 16;9(1):e1100. doi: 10.1212/NXI.0000000000001100. Print 2022 Jan. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34785575 Free PMC article.
BACKGROUND AND OBJECTIVES: To evaluate the long-term safety and efficacy of tocilizumab (TCZ), a humanized anti-interleukin-6 receptor antibody in myelin oligodendrocyte glycoprotein-IgG-associated disease (MOGAD) and neuromyelitis optica spectrum disorders (NMOSD). ...DIS …
BACKGROUND AND OBJECTIVES: To evaluate the long-term safety and efficacy of tocilizumab (TCZ), a humanized anti-interleukin-6 recepto …
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort.
Comarmond C, Pagnoux C, Khellaf M, Cordier JF, Hamidou M, Viallard JF, Maurier F, Jouneau S, Bienvenu B, Puéchal X, Aumaître O, Le Guenno G, Le Quellec A, Cevallos R, Fain O, Godeau B, Seror R, Dunogué B, Mahr A, Guilpain P, Cohen P, Aouba A, Mouthon L, Guillevin L; French Vasculitis Study Group. Comarmond C, et al. Arthritis Rheum. 2013 Jan;65(1):270-81. doi: 10.1002/art.37721. Arthritis Rheum. 2013. PMID: 23044708 Free article.
This study was undertaken to describe the main characteristics of a larger patient cohort and their long-term outcomes. METHODS: A retrospective study of EGPA patients in the French Vasculitis Study Group cohort who satisfied the American College of Rheumatology criteria a …
This study was undertaken to describe the main characteristics of a larger patient cohort and their long-term outcomes. METHODS: A re …
Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.
Bigaut K, Fabacher T, Kremer L, Ongagna JC, Kwiatkowski A, Sellal F, Ferriby D, Courtois S, Vermersch P, Collongues N, Zéphir H, De Seze J, Outteryck O. Bigaut K, et al. Among authors: zephir h. Mult Scler. 2021 Apr;27(5):729-741. doi: 10.1177/1352458520936239. Epub 2020 Jul 9. Mult Scler. 2021. PMID: 32643521
BACKGROUND: Data are needed on long-term effect of natalizumab (NTZ) in relapsing-remitting multiple sclerosis (RRMS). ...
BACKGROUND: Data are needed on long-term effect of natalizumab (NTZ) in relapsing-remitting multiple sclerosis (RRMS). ...
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis.
Benallegue N, Rollot F, Wiertlewski S, Casey R, Debouverie M, Kerbrat A, De Seze J, Ciron J, Ruet A, Labauge P, Maillart E, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Berger E, Stankoff B, Clavelou P, Heinzlef O, Pelletier J, Thouvenot E, Al Khedr A, Bourre B, Casez O, Cabre P, Wahab A, Magy L, Vukusic S, Laplaud DA; OFSEP (Observatoire Français de la Sclérose en Plaques) Investigators. Benallegue N, et al. Among authors: zephir h. JAMA Neurol. 2024 Mar 1;81(3):273-282. doi: 10.1001/jamaneurol.2023.5566. JAMA Neurol. 2024. PMID: 38345791 Free PMC article.
These findings suggest prioritizing initial HET in POMS, although long-term safety studies are needed....
These findings suggest prioritizing initial HET in POMS, although long-term safety studies are needed....
Assessing Sustained B-Cell Depletion and Disease Activity in a French Multiple Sclerosis Cohort Treated by Long-Term IV Anti-CD20 Antibody Therapy.
Freeman SA, Lemarchant B, Alberto T, Boucher J, Outteryck O, Labalette M, Rogeau S, Dubucquoi S, Zéphir H. Freeman SA, et al. Among authors: zephir h. Neurotherapeutics. 2023 Oct;20(6):1707-1722. doi: 10.1007/s13311-023-01446-5. Epub 2023 Oct 26. Neurotherapeutics. 2023. PMID: 37882961 Free PMC article.
Few studies have investigated sustained B-cell depletion after long-term intravenous (IV) anti-CD20 B-cell depleting therapy (BCDT) in multiple sclerosis (MS) with respect to strict and/or minimal disease activity. ...Furthermore, we assessed the frequency of serious adver …
Few studies have investigated sustained B-cell depletion after long-term intravenous (IV) anti-CD20 B-cell depleting therapy (BCDT) i …
Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference.
Gavoille A, Rollot F, Casey R, Debouverie M, Le Page E, Ciron J, De Seze J, Ruet A, Maillart E, Labauge P, Zephir H, Papeix C, Defer G, Lebrun-Frenay C, Moreau T, Laplaud DA, Berger E, Stankoff B, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al Khedr A, Casez O, Bourre B, Cabre P, Wahab A, Magy L, Camdessanche JP, Maurousset A, Moulin S, Ben NH, Boulos DD, Hankiewicz K, Neau JP, Pottier C, Nifle C, Rabilloud M, Subtil F, Vukusic S; Observatoire Français de la Sclérose en Plaques (OFSEP) Investigators. Gavoille A, et al. Among authors: zephir h. Neurology. 2023 Mar 21;100(12):e1296-e1308. doi: 10.1212/WNL.0000000000206774. Epub 2022 Dec 23. Neurology. 2023. PMID: 36564207 Free PMC article.
BACKGROUND AND OBJECTIVES: The question of the long-term safety of pregnancy is a major concern in patients with multiple sclerosis (MS), but its study is biased by reverse causation (women with higher disability are less likely to experience pregnancy). Using a causal inf …
BACKGROUND AND OBJECTIVES: The question of the long-term safety of pregnancy is a major concern in patients with multiple sclerosis ( …
Anti-CD20 monoclonal antibodies in multiple sclerosis: Rethinking the current treatment strategy.
Freeman SA, Zéphir H. Freeman SA, et al. Among authors: zephir h. Rev Neurol (Paris). 2024 Apr 9:S0035-3787(24)00474-0. doi: 10.1016/j.neurol.2023.12.013. Online ahead of print. Rev Neurol (Paris). 2024. PMID: 38599976 Review.
While these new strategies show efficacy in maintaining inflammatory MS disease control, and although it is tempting to speculate that tailoring CD20 therapies will reduce the negative outcomes of long-term immunosuppression, it is unknown whether they provide meaningful b …
While these new strategies show efficacy in maintaining inflammatory MS disease control, and although it is tempting to speculate that tailo …
The long-term outcome of MOGAD: An observational national cohort study of 61 patients.
Deschamps R, Pique J, Ayrignac X, Collongues N, Audoin B, Zéphir H, Ciron J, Cohen M, Aboab J, Mathey G, Derache N, Laplaud D, Thouvenot E, Bourre B, Ruet A, Durand-Dubief F, Touitou V, Vignal-Clermont C, Papeix C, Gout O, Marignier R, Maillart E; NOMADMUS study group. Deschamps R, et al. Among authors: zephir h. Eur J Neurol. 2021 May;28(5):1659-1664. doi: 10.1111/ene.14746. Epub 2021 Feb 19. Eur J Neurol. 2021. PMID: 33528851
Finally, 12.5% of patients presented bladder dysfunction requiring long-term urinary catheterization. No factor associated significantly with a final EDSS score 3 or with final VA 0.1 was found. CONCLUSION: Overall long-term favourable outcomes were achieved in a ma …
Finally, 12.5% of patients presented bladder dysfunction requiring long-term urinary catheterization. No factor associated significan …
[Neuropsychiatric systemic lupus erythematosus (2nd part). Diagnostic and treatment tools in psychiatric or central nervous system manifestations in systemic lupus erythematosus].
Lefèvre G, Zéphir H, Michelin E, Semah F, Warembourg F, Pruvo JP, Hachulla E, Lenfant P, Dubucquoi S, Vermersch P, Hatron PY, Prin L, Launay D. Lefèvre G, et al. Among authors: zephir h. Rev Med Interne. 2012 Sep;33(9):503-13. doi: 10.1016/j.revmed.2012.03.354. Epub 2012 May 9. Rev Med Interne. 2012. PMID: 22578589 Review. French.
Neurological and psychiatric manifestations of systemic lupus erythematosus are a heterogeneous set of clinical manifestations grouped under the term of "neuropsychiatric systemic lupus erythematosus". The classification of these manifestations published in 1999 has harmon …
Neurological and psychiatric manifestations of systemic lupus erythematosus are a heterogeneous set of clinical manifestations grouped under …
[Immunosuppression with monoclonal antibodies in multiple sclerosis].
Vermersch P, Zéphir H. Vermersch P, et al. Among authors: zephir h. Rev Neurol (Paris). 2007 Jun;163(6-7):682-7. doi: 10.1016/s0035-3787(07)90480-4. Rev Neurol (Paris). 2007. PMID: 17607190 Review. French.
In a combination study with interferon beta-1a, two cases of progressive multifocal leukoencephalopathy, one of which was fatal, were diagnosed in natalizumab-treated patients. The safety of long-term use of natalizumab treatment is unknown. Promising results have been sho …
In a combination study with interferon beta-1a, two cases of progressive multifocal leukoencephalopathy, one of which was fatal, were diagno …
18 results